Prescient Therapeutics Limited ((AU:PTX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Prescient Therapeutics Limited is conducting an open-label, phase 2 study titled ‘An Open-Label, Phase 2 Study of PTX-100 Monotherapy in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.’ The study aims to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of PTX-100 in patients with relapsed or refractory CTCL, a rare type of cancer affecting the skin.
The intervention being tested is PTX-100, a peptidomimetic inhibitor of GGTase 1, administered via intravenous infusion. The study involves two dosage levels, 500 mg/m2 and 1000 mg/m2, to determine the optimal dose for further development.
This interventional study is randomized with a parallel assignment model and no masking, focusing primarily on treatment. It is designed to assess the treatment’s impact over a series of cycles, initially in a 14-day cycle followed by a 21-day cycle.
The study began on February 18, 2025, with the last update submitted on August 3, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
The study’s progress could influence Prescient Therapeutics’ stock performance, as positive results may enhance investor confidence and position the company favorably against competitors in the oncology sector.
The study is currently recruiting, with further details available on the ClinicalTrials portal.